Skip to main content
Premium Trial:

Request an Annual Quote

Software Firm Proventys Raises $3.3M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Personalized medicine software firm Proventys has raised nearly $3.3 million in an offering it hopes will bring in a total of $5.1 million, the firm said in a document filed with the US Securities and Exchange Commission.

The company did not say how the funds would be used.

A total of seven individuals participated in the offering including current Proventys directors Ralph Synderman, Proventys' founder and chairman of the board; Steven Burrill, CEO of VC firm Burrill & Co.; and David Lawrence, former CEO and chairman of Kaiser Foundation Health Plan and Kaiser Foundation Hospitals.

Proventys is based in Durham, NC, and according to its website, its main platform, called the Proventys PDx System, incorporates statistical models that leverage clinical data and biomarkers to quantify a patient's chances of developing a disease or adverse event, or predict response to a therapy.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.